BACKGROUND: The Veterans Aging Cohort Study (VACS) Index, a composite marker of disease severity among human immunodeficiency virus (HIV)-infected persons, has been associated with concurrent risk for neurocognitive impairment (NCI). The present study examined whether the VACS Index predicts longitudinal neurocognitive change. METHODS: Participants included 655 HIV-infected persons followed for up to 6 years in cohort studies at the University of California, San Diego, HIV Neurobehavioral Research Program (mean age at baseline, 42.5 years; 83% male; 60% white; AIDS in 67%; median current CD4(+) T-cell count, 346/μL; 61% receiving antiretroviral therapy). The VACS Index was calculated through standard methods. Participants completed a comprehensive neurocognitive battery. Neurocognitive status was plotted over time using demographically and practice-adjusted global and domain T scores. NCI was defined by global deficit scores derived from T scores. RESULTS: Baseline VACS Index scores were not predictive of changes in global T scores during the follow-up period (P = .14). However, in time-dependent analyses adjusting for covariates, higher VACS Index scores were significantly associated with worse global and domain neurocognitive performance (Ps < .01), as well as increased risk for developing NCI in a subgroup of persons who were neurocognitively normal at baseline (hazard ratio [HR], 1.17; P < .001). We categorized VACS Index scores by quartiles and found that the upper-quartile group was significantly more likely to develop NCI than the lower quartile (HR, 2.16; P < .01) and middle groups (HR, 1.76; P < .01). CONCLUSIONS: Changes in VACS Index scores correspond to changes in neurocognitive function. HIV-infected persons with high VACS Index scores are at increased risk for decline and incident NCI. The VACS Index shows promise as a tool for identifying HIV-infected persons at risk for NCI.
BACKGROUND: The Veterans Aging Cohort Study (VACS) Index, a composite marker of disease severity among human immunodeficiency virus (HIV)-infectedpersons, has been associated with concurrent risk for neurocognitive impairment (NCI). The present study examined whether the VACS Index predicts longitudinal neurocognitive change. METHODS:Participants included 655 HIV-infectedpersons followed for up to 6 years in cohort studies at the University of California, San Diego, HIV Neurobehavioral Research Program (mean age at baseline, 42.5 years; 83% male; 60% white; AIDS in 67%; median current CD4(+) T-cell count, 346/μL; 61% receiving antiretroviral therapy). The VACS Index was calculated through standard methods. Participants completed a comprehensive neurocognitive battery. Neurocognitive status was plotted over time using demographically and practice-adjusted global and domain T scores. NCI was defined by global deficit scores derived from T scores. RESULTS: Baseline VACS Index scores were not predictive of changes in global T scores during the follow-up period (P = .14). However, in time-dependent analyses adjusting for covariates, higher VACS Index scores were significantly associated with worse global and domain neurocognitive performance (Ps < .01), as well as increased risk for developing NCI in a subgroup of persons who were neurocognitively normal at baseline (hazard ratio [HR], 1.17; P < .001). We categorized VACS Index scores by quartiles and found that the upper-quartile group was significantly more likely to develop NCI than the lower quartile (HR, 2.16; P < .01) and middle groups (HR, 1.76; P < .01). CONCLUSIONS: Changes in VACS Index scores correspond to changes in neurocognitive function. HIV-infectedpersons with high VACS Index scores are at increased risk for decline and incident NCI. The VACS Index shows promise as a tool for identifying HIV-infectedpersons at risk for NCI.
Authors: Kathleen M Akgün; Janet P Tate; Kristina Crothers; Stephen Crystal; David A Leaf; Julie Womack; Todd T Brown; Amy C Justice; Krisann K Oursler Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: María J Marquine; Anya Umlauf; Alexandra S Rooney; Pariya L Fazeli; Ben D Gouaux; Steven Paul Woods; Scott L Letendre; Ronald J Ellis; Igor Grant; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Lucette A Cysique; Donald Franklin; Ian Abramson; Ronald J Ellis; Scott Letendre; Ann Collier; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2011-03-07 Impact factor: 2.475
Authors: Gerome V Escota; Pragna Patel; John T Brooks; Tim Bush; Lois Conley; Jason Baker; Erna Milunka Kojic; John Hammer; Nur F Önen Journal: AIDS Res Hum Retroviruses Date: 2015-01-20 Impact factor: 2.205
Authors: Julie A Womack; Joseph L Goulet; Cynthia Gibert; Cynthia A Brandt; Melissa Skanderson; Barbara Gulanski; David Rimland; Maria C Rodriguez-Barradas; Janet Tate; Michael T Yin; Amy C Justice Journal: Clin Infect Dis Date: 2013-02-01 Impact factor: 9.079
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Kathleen M Akgün; Kirsha Gordon; Margaret Pisani; Terri Fried; Kathleen A McGinnis; Janet P Tate; Adeel A Butt; Cynthia L Gibert; Laurence Huang; Maria C Rodriguez-Barradas; David Rimland; Amy C Justice; Kristina Crothers Journal: J Acquir Immune Defic Syndr Date: 2013-01-01 Impact factor: 3.731
Authors: M J Marquine; M Sakamoto; C Dufour; A Rooney; P Fazeli; A Umlauf; B Gouaux; D Franklin; R Ellis; S Letendre; M Cherner; R K Heaton; I Grant; D J Moore Journal: J Neurovirol Date: 2015-12-17 Impact factor: 2.643
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Syki Duong; Samantha Mawhinney; Wendy M Kohrt; Thomas B Campbell Journal: HIV Clin Trials Date: 2012 Nov-Dec
Authors: Kristine M Erlandson; Jeremiah Perez; Mona Abdo; Kevin Robertson; Ronald J Ellis; Susan L Koletar; Robert Kalayjian; Babafemi Taiwo; Frank J Palella; Katherine Tassiopoulos Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079
Authors: Rowan Saloner; Robert K Heaton; Laura M Campbell; Anna Chen; Donald Franklin; Ronald J Ellis; Ann C Collier; Christina Marra; David B Clifford; Benjamin Gelman; Ned Sacktor; Susan Morgello; J Allen McCutchan; Scott Letendre; Igor Grant; Christine Fennema-Notestine Journal: AIDS Date: 2019-06-01 Impact factor: 4.177
Authors: Kalei R J Hosaka; Meredith Greene; Thomas A Premeaux; Shireen Javandel; Isabel E Allen; Lishomwa C Ndhlovu; Victor Valcour Journal: J Am Geriatr Soc Date: 2019-06-26 Impact factor: 5.562
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492
Authors: Ronald A Cohen; Joseph M Gullett; Eric C Porges; Adam J Woods; Damon G Lamb; Vaughn E Bryant; Mikayla McAdams; Karen Tashima; Robert Cook; Kendall Bryant; Mollie Monnig; Christopher W Kahler; Peter M Monti Journal: Alcohol Clin Exp Res Date: 2018-12-16 Impact factor: 3.455
Authors: Lily Kamalyan; Mariam A Hussain; Monica M Diaz; Anya Umlauf; Donald R Franklin; Mariana Cherner; Monica Rivera Mindt; Lidia Artiola I Fortuny; Igor Grant; Robert K Heaton; María J Marquine Journal: Clin Neuropsychol Date: 2019-12-17 Impact factor: 3.535
Authors: Yunan Xu; Yizi Lin; Ryan P Bell; Sheri L Towe; John M Pearson; Tauseef Nadeem; Cliburn Chan; Christina S Meade Journal: J Neurovirol Date: 2021-01-19 Impact factor: 2.643
Authors: Vincent J Maffei; Tekeda F Ferguson; Meghan M Brashear; Donald E Mercante; Katherine P Theall; Robert W Siggins; Christopher M Taylor; Patricia Molina; David A Welsh Journal: AIDS Date: 2020-02-01 Impact factor: 4.632